908 Devices (MASS) investor relations material

Strategic transformation and market positioning

• Divested the desktop bioprocessing portfolio in 2025 to focus exclusively on handheld chemical detection for public health, safety, and defense markets.

• Launched a strategic transformation with "908 Devices 2.0," achieving sharper operational alignment, improved financials, and a clear growth strategy.

• Achieved 18% year-over-year revenue growth in 2025 and 14% YoY growth in Q1 2026, with a healthy balance sheet and $111.7M cash at quarter end.

• Diversified customer base, reducing reliance on large federal contracts and increasing state, local, and international sales.

• Targeting a $1.5B TAM in 2026 and $2.5B in 2027, with a 20,000+ device opportunity post-NIRLAB acquisition.

Product innovation and portfolio expansion

• Developed a comprehensive suite of handheld devices, including MX908 (mass spectrometry), XplorIR, VipIR (FTIR and Raman), ProtectIR, and ThreatID, covering gas/vapor, trace, and bulk identification.

• Acquired NIRLAB AG in May 2026, adding a cloud-connected, AI-driven, subscription-based device for frontline law enforcement, with over 100 active customers, high recurring revenue, and >99% retention.

• NIRLAB brings the world's largest NIR and FReD spectral database for narcotics, supported by AI and machine learning.

• Devices and the TeamLeader app are integrated into a cloud platform for unified workflows, data aggregation, geospatial mapping, fleet management, and AI-powered guidance.

• Platform supports integrations with drones, UGVs, and OEM partnerships in industrial QA/QC and pharma.

Addressing global threats and customer impact

• Addressing urgent threats such as the opioid crisis, toxic industrial materials, and rising global defense needs, with U.S. federal designation of fentanyl as a Weapon of Mass Destruction and increased NATO defense spending driving demand.

• Devices deployed in over 70 countries, with nearly 3,900 units and 18,000+ trained users across law enforcement, fire/hazmat, and military sectors.

• State and local customers now represent about 50% of revenues, providing stable and predictable demand.

• Real-world impact demonstrated by Operation FREE in Virginia, reducing correctional facility overdoses to zero.

• Devices support rapid screening, trace detection, and broad chemical identification for frontline and specialist operations.